Weave Communications, Inc. (WEAV) · Oct 13, 2026 · Acquisition
Merger disclosures supplemented — 2 complaints and 13 demand letters; merger consideration and October 22 meeting unchanged
Weave’s merger 8-K discloses two lawsuits and 13 demand letters over proxy disclosures. The $7.40 cash deal and October 22 vote remain unchanged.
Weave is a vertical SaaS company building AI-powered patient engagement and payment tools for small and midsized healthcare practices. This filing is not a change to that operating story; it is a procedural update around Francisco Partners’ already-announced take-private transaction.
The new issue is litigation and shareholder pressure, not a renegotiated deal. Weave discloses two complaints and 13 demand letters alleging that its proxy statement omitted or misstated information about the merger. 〔0〕 〔1〕
Management is buying procedural certainty by adding disclosures it says are immaterial. The company denies that the original proxy was legally deficient, but is supplementing it to reduce the risk that the lawsuits delay the special meeting or closing. 〔2〕
| Merger-analysis item | Filing figure |
|---|---|
| Estimated 2026 revenue | $279.6 million (Selected Publicly Traded Companies Analysis) |
| Estimated 2027 revenue | $328.1 million (Selected Publicly Traded Companies Analysis) |
| Estimated 2027 adjusted EBITDA | $30.5 million (Selected Publicly Traded Companies Analysis) |
| Last-twelve-month revenue | $257.8 million (Selected Precedent Transactions Analysis) |
| Implied value per share from precedent transactions | $6.60–$9.51 (Selected Precedent Transactions Analysis) |
| Implied value per share from DCF | $6.25–$8.08 (Discounted Cash Flow Analysis) |
| Net cash | $64.0 million (Discounted Cash Flow Analysis) |
The supplemental valuation detail does not change the transaction economics. The filing adds corrected or expanded banker-analysis figures, including the precedent-transaction and DCF ranges, but it does not disclose a higher offer, a lower offer, or a revised recommendation. The company explicitly says the merger consideration and meeting timing are unaffected. 〔3〕
The practical takeaway is modest execution risk around an otherwise intact deal. The complaints seek to delay or enjoin the merger, but the board continues to recommend approval and the October 22, 2026 special meeting remains scheduled. 〔4〕
Bottom line: This adds nuisance litigation and disclosure friction to the merger process, but does not change the offer, recommendation, or vote schedule. It matters mainly as a closing-process risk, not as a new view on Weave’s underlying business or the deal’s value.
Stockholder vote on merger, October 22, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!